Author

F Mansaray

Observed name: Foday Tejan Mansaray

Institution: King's College London

Observed institutions: King's College London, London School of Hygiene & Tropical Medicine, Mwanza Intervention Trials Unit, National Institute for Medical Research

OpenAlex ID: A5113962472

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

2021 · Muhammed O Afolabi, David Ishola, et al. · The Lancet Infectious Diseases · 94

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

2021 · David Ishola, Daniela Manno, et al. · The Lancet Infectious Diseases · 93

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

2023 · Edward Man-Lik Choi, Boris Lacarra, et al. · The Lancet Global Health · 18

Emergency care capacity in Sierra Leone: A multicentre analysis

2024 · Zosia Bredow, Zoe Corbett, et al. · African Journal of Emergency Medicine · 4

Works count: 4

Citation count: 209

H-index: 4

I10-index: 3